McKetin, Rebecca http://orcid.org/0000-0003-2833-4830
Dean, Olivia M.
Turner, Alyna
Kelly, Peter J.
Quinn, Brendan
Lubman, Dan I.
Dietze, Paul
Carter, Gregory
Higgs, Peter
Baker, Amanda L.
Sinclair, Barbara
Reid, David
Manning, Victoria
te Pas, Nina
Liang, Wenbin
Thomas, Tamsin
Bathish, Ramez
Kent, Margaret
Raftery, Dayle
Arunogiri, Shalini
Cordaro, Frank
Hill, Harry
Berk, Michael
Funding for this research was provided by:
Australian National Health and Medical Research Council (1128147)
Article History
Received: 9 November 2018
Accepted: 16 May 2019
First Online: 4 June 2019
Ethics approval and consent to participate
: This trial has been approved by all relevant human research ethics committees: Eastern Health (E21β2017), Barwon Health (17/202), the University of Wollongong and the Illawarra Shoalhaven Local Health District Health (2017/549) and Curtin University (HRE2018β0205). All participants provide informed consent prior to participation.
: Not applicable.
: OMD has received grant support from Lilly and ASBDD/Servier and in-kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. MB has received grant support from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, the Meat and Livestock Board, Novartis, Mayne Pharma and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Servier. DIL has provided consultancy advice to Lundbeck and Indivior, and has received travel support and speaker honoraria from Astra Zeneca, Indivior, Janssen, Lundbeck, Servier and Shire. PD has received investigator-initiated funding from Gilead Sciences, an untied educational grant from Indivior and is an unpaid member of an advisory board for Mundipharma for work unrelated to this study.